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Background: Marfan syndrome (MFS) is a genetically determined multiorgan disease that leads to severe 
physiological and psychological impairments in adult life. Little consensus exists regarding quality of life 
(QOL) in individuals with MFS. The present study sought to investigate QOL in a representative cohort of 
adults with MFS.
Methods: Patient-reported outcome measures from a representative sample of 102 adults with MFS 
(39.3±13.1 years of age; 40.2% female) were retrospectively analyzed and compared with those from adults 
with different congenital heart defects (CHD), at the German Heart Center Munich. QOL was assessed 
using the updated five-level version of the EQ-5D.
Results: Differences between both populations were analyzed. Subjects affected by MFS reported an 
overall reduced QOL. Compared to CHD patients, individuals with MFS scored significantly lower in the 
dimensions of pain/discomfort, anxiety/depression, mobility and usual activities (P<0.05). 
Conclusions: Patients with MFS are at high risk for impaired QOL, especially in mental and physical 
domains. Psychosocial consequences of MFS cost resources for both, patients and professionals. Current 
findings highlight the great importance of additional psychological support to cope with disease-related 
challenges. Increased attention should be directed towards enhancing their subjective wellbeing to potentially 
improve their QOL and long-term health outcomes. 
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Introduction
Marfan syndrome (MFS) is a genetically determined 
multiorgan disease that affects the connective tissue 
throughout the body, including the skeletal, ocular, pulmonary, 
cardiovascular, and central nervous systems. An estimated 
proportion of 0.002% to 0.017% of the population is affected 
by MFS (1). The most severe complications from a medical 
perspective include aneurysm formation and dissection of the 
aorta. Consequently, most patients are closely monitored, 
with serial cardiovascular assessments from early childhood 
(2-5). Additionally, patients with MFS often have to cope with 
skeletal or ocular abnormalities leading to a characteristic 
appearance, which is not only subjectively perceived by 
themselves, but is also visible to others (6,7). Recent studies 
have indicated that the combination of physiological and 
psychological symptoms may lead to a decreased quality of life 
(QOL) in individuals with MFS (3).
Despite the growing interest in psychosocial consequences 
for patients with congenital heart defects (CHD), research on 
the particular psychological concerns of individuals with MFS is 
still scarce (8). While clinical research has traditionally focused 
on “hard” outcome measures, such as morality, morbidity, and 
functional status, the concept of QOL has become increasingly 
recognized as an important patient-reported outcome measure 
in the evaluation of care and treatment (9). Patients with 
MFS present an elevated risk for adverse psychosocial outcomes, 
including decreased QOL, particularly in the psychological 
domain (3,4,10-12). Some patients with MFS also experience 
symptoms of emotional distress, such as depression and 
anxiety (4,7,13). Emotional distress can impact a patient’s 
overall health and lead to increased cardiovascular morbidity 
and premature mortality (14,15).
The present study aimed to (I) systematically assess 
QOL within a large sample of patients affected by MFS 
and (II) compare the results with findings on patients with 
other types of CHD. In an attempt to raise awareness for 
the psychosocial implications of MFS, this study should 
encourage clinicians to evaluate the psychological status of 
patients with MFS and, on the basis of this status, enhance 
treatment options. We present the following article in 




The present study represents a subgroup analysis of the 
nation-wide VEMAH study (www.vemah.info) which 
constitutes the first large-scale attempt to comprehensively 
assess the health care situation of a large cohort of adults 
with congenital heart disease (ACHD) in Germany. The 
questionnaire-based survey was initiated and carried out by 
the Department of Congenital Heart Disease of the German 
Heart Centre Munich, Technical University Munich, and 
the Department of Cardiology, University of Erlangen. The 
insurance company “AOK Bayern” supported the study 
by sending out our questionnaires to their insured ACHD 
patients in Bavaria. The study was conducted in accordance 
with the Declaration of Helsinki (as revised in 2013) 
and under the approval of the Ethics Committee of the 
Technical University of Munich (157 / 16 S). Data collection 
took place between May 2017 and July 2020. Written 
informed consent was obtained from all participating 
patients before the start of documentation. Guidelines on 
good pharmacoepidemiologic practice and data protection 
guidelines were followed. 
Patients were selected for sub-analysis according to 
the following inclusion criteria: (I) confirmed diagnosis of 
MFS; (II) participant age 18 years or older; (III) necessary 
physical, cognitive and language capabilities to complete 
self-report questionnaires; (IV) German speaking. 
Participants were excluded if they did not fulfill age 
requirements or had severely impaired cognitive abilities. 
Patients were consecutively included in the order that they 
presented at the institution and were not selected in prior.
Measures
Patient-reported outcome measures were assessed by a 
specifically devised questionnaire in cooperation with 
the Chair of Behavioral Epidemiology at the Technical 
University of Dresden and the German Heart Center 
Munich. The questionnaire was completed in person, 
online or by mail. Data collection took place between 2016 
and 2019. QOL was measured using the updated five-
level version of the EQ-5D (EQ-5D-5L) which provides 
a simple, generic measure of a patient’s perceived health 
status. Research has shown that this version presents a 
significantly higher reliability and discriminatory power 
and reduces ceiling effects, , compared with the original 
EQ-5D (16). The EQ-5D-5L is a paper-based, self-
complete questionnaire consisting of two sections: a 
descriptive system questionnaire and a visual analogue scale 
(VAS). The descriptive system compromises five dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
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anxiety/depression. The patient is asked to indicate his 
or her perceived impairments on a 5-point Likert scale 
ranging from “no problems” to “extreme problems/unable”. 
Responses are coded as single-digit numbers expressing 
the severity of impairment on each dimension. Responses 
can be converted into a single weighted index score (EQ-
5D index) using population preference scores. A value set 
for the EQ-5D-5L based on a representative sample of 
the German population has recently been developed (17). 
The EQ-VAS indicates a patient’s overall health state on a 
vertical scale which ranges from 0 (“The worst health you 
can imagine”) to 100 (“The best health you can imagine”). 
It therefore provides a quantitative measure of a patient’s 
perceived health.
Statistical analysis
Statistical analysis was performed using SPSS 25.0 (IBM 
Inc., Armonk, NY, USA). Medical records were reviewed 
for patient demographics, cardiac and non-cardiac 
diagnoses. Statistical evaluations were pseudonymized and 
not linked to individual person. Descriptive measures were 
calculated for sociodemographic sample characteristics. 
Several logistic regression models were calculated to 
analyse the impact of MFS on descriptive QOL dimensions, 
using the EQ-dimensions of the EQ-5D-5L as dependent 
variables. Differences between the populations were 
evaluated using the chi-squared tests. T-tests were used 
for comparisons between mean values. Continuous data 
was expressed as mean ± standard deviation, categorical or 
interval scaled variables as absolute numbers or percentages. 
The crosswalk-index-value (utility index) of the EQ5D-
5L was calculated using the German value set (17). All 
occurring P values and tests for significance were performed 
in a two-sided manner. Statistical significance was indicated 
by a P value <0.05. 
Results
Sample characteristics 
Out of 3,885 patients, a total of 102 patients with MFS were 
retained for the final analysis (40.2% female) (Table 1). The 
mean age of the patients with MFS was 39.3±13.1 (range, 
20–85) years. The remaining 3,783 ACHD [42.0±17.3 
(range, 18–97) years; 46.6% female] were consulted to offer 
a point of reference consisting of non-MFS ACHD. Both 
populations were comparable in their age distribution, 
residential zone and insurance status. 
QOL in patients with MFS
Table 2 shows the impact of MFS on all five QOL dimensions. 
Having MFS significantly decreased the odds of experiencing 
no difficulties on all respective dimensions (P<0.05), except 
for self-care. Similar results are reflected in Table 3, which 
compares the subscales of the EQ-5D-5L for the MFS 
sample and for the chosen comparison group of ACHD. 
Compared to the larger ACHD group, patients with 
MFS reported significantly worse QOL in usual activities 
(P=0.002), pain/discomfort (P≤0.001), and anxiety/
depression (P=0.022). Observed differences were most 
extreme on the pain/discomfort dimension. No significant 
differences were observed on the self-care (P=0.483) 
or mobility (P=0.059) dimensions. Figure 1 is a graphic 
representation of the comparison between the 5 dimensions 
of the EQ-5D-5L for both samples. 
When comparing the combined measures of QOL 
between patients with MFS and non-MFS ACHD (Table 4), 
patients with MFS scored markedly lower on the VAS 
(P=0.073) and also had lower descriptive index values 
(P=0.025). However, the observed differences between the 
populations were less extreme in regard to the VAS scores. 
Additionally, the observed variations in QOL depended on 
the type of measurement applied. Accordingly, the mean 
VAS score was markedly lower than the descriptive index 
value for QOL. 
Discussion
In recent decades, substantial medical advancements have 
improved the lives of individuals with MFS. Consequently, 
many clinicians count MFS among the most manageable 
of genetic conditions today (7). However, many affected 
patients do not share this view and describe considerable 
impairments in their QOL (4). Remarkably few studies have 
been undertaken to assess psychosocial consequences of 
MFS. The major purpose of this study was to explore QOL 
among individuals with MFS and elaborate on previous 
findings by utilizing the EQ-5D-5L, a highly reliable and 
valid outcome measure within the cardiovascular area (18). 
It includes two types of measurement, a short descriptive 
system questionnaire and a VAS, and therefore holds a more 
global view on QOL in terms of general life satisfaction. 
The current study provides evidence that patients with 
MFS are at particularly high risk for a diminished QOL and 
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present major mental and physiological impairments. 
The study encompassed a nationwide sample of patients 
with MFS recruited by the German Heart Center Munich. 
It was ensured that the reference data were ascertained 
with the same methods to ensure maximum comparability 
between the two populations. 
Nonetheless, the present study may be subject to certain 
limitations. First, the study was cross-sectional in nature 
and does not allow any conclusions to be drawn regarding 
the etiology of psychological and physiological effects or 
the development in QOL over time. Second, as data were 
assessed retrospectively, it was not possible to determine 
precise response rates among the respondents. Third, the 
study relied on self-report outcomes and might be subject to 
recall and self-presentation bias. Fourth, as the enrolment 
was voluntary, selection bias could not be excluded and may 
limit representativeness. Fifth, this study was performed 
at tertiary care centers for ACHD which does not reflect 
the typical population of CHD patients, who most often 
present to non-specialized physicians. Sixth, the data derived 
only from patients living in Germany and generalization 
of the conclusions to the greater, global MFS population is 
debatable. Finally, since no control group was involved in 
the original study design, data could only be compared to 
the remaining respondents affected by a variety of types of 
CHD. In order to put findings into appropriate perspective, 
control group designs are conceivable in future clinical trials.
Table 1 Characteristics of the study populations 
Demographics Marfan (n=102) ACHD (n=3,783)
Age (in years) 39.3±13.1 [20–85] 42.0±17.3 [18–97]
Sex (female), n (%) 41 (40.2%) 1,763 (46.6%)
Age group (in years), n (%)
18–34 41 (40.2) 1,604 (42.4)
35–64 55 (53.9) 1,678 (44.4)
65+ 6 (5.9) 501 (13.2)
Missing (n) 0 111
Residence n (%)
City 26 (25.7) 747 (20.0)
Town 14 (13.9) 571 (15.3)
Rural 61 (60.4) 2,418 (64.7)
Missing (n) 1 158
Insurance n (%)
Public 93 (93.0) 3,570 (94.3)
Private 7 (7.0) 210 (5.5)
No insurance 0 (0.0) 7 (0.2)
Missing (n) 2 107
ACHD, adults with congenital heart defects; n, absolute number.





Usual activities 0.487* (0.32–0.75)
Pain/discomfort 0.370* (0.25–0.55)
Anxiety/depression 0.598* (0.40–0.90)
Displayed is the odds ratio, upper and lower bounds (95% CI) 
respectively which was obtained from several ordered logistic 
regressions using EQ-dimensions as dependent variable. *, 
P<0.05. 
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n % n %
Mobility
No problems 62 66.7 2,820 76.0 0.059
Slight problems 18 19.4 449 12.1
Moderate problems 10 10.8 309 8.3
Severe problems 2 2.2 117 3.2
Unable to walk 1 1.1 17 0.4
Missing 9 – 182 –
Self-care
No problems 88 94.6 3,442 92.8 0.483
Slight problems 3 3.2 141 3.8
Moderate problems 1 1.1 70 1.9
Severe problems 1 1.1 33 0.9
Unable to wash/dress 0 0.0 25 0.7
Missing 9 – 183 –
Usual activities
No problems 51 54.8 2,599 70.2 0.002*
Slight problems 23 24.7 619 16.7
Moderate problems 13 14.0 320 8.6
Severe problems 6 6.5 119 3.2
Unable to do 0 0.0 44 1.2
Missing 9 – 193 –
Pain/discomfort
No pain 30 32.6 2,154 58.7 <0.001*
Slight pain 39 42.4 922 25.1
Moderate pain 16 17.4 450 12.3
Severe pain 7 7.6 130 3.5
Extreme pain 0 0.0 15 0.4
Missing 10 – 223 –
Anxiety/depression
Not anxious/depressed 43 46.2 2,181 59.2 0.022*
Slightly anxious/depressed 33 35.5 981 26.6
Moderately anxious/depressed 14 15.1 346 9.4
Severely anxious/depressed 3 3.2 148 4.0
Extremely anxious/depressed 0 0.0 31 0.8
Missing 9 – 207 –
*, significant finding. ACHD, adults with congenital heart defects; n, absolute number. 
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QOL in patients with MFS
Pain/discomfort
Current findings indicate that QOL of patients with 
MFS is significantly compromised in the physical domain 
compared to counterparts with other forms of CHD. 
Indeed, previous research has demonstrated that the 
percentage of MFS patients suffering from chronic pain 
ranges from 47% to 92% and that this is a significant 
and persistent problem in MFS (19). According to recent 
findings related to pain in individuals with MFS, pain is a 
major contributor to decreased QOL (4). The most severe 
types of pain include back pain followed by neck pain and 
headaches (20). Clinical manifestations of MFS, such as 
dural ectasia, degenerative disk disease, kyphosis and early 
osteo-arthritis frequently cause great pain (4). However, 
treatment options for chronic pain management are still 
lacking and research efforts in this area appear fragmented. 
In a survey of 993 patients with MFS, Nelsen et al. noted 
that very few patients receive medical procedures for pain 
and less than a half of them are satisfied with their current 
pain treatment (21). These findings are especially worrying 
since chronic pain is linked to profound disability and 
significant psychological burden (19). Further research is 
needed to characterize, in greater depth, the directionality 
of pain, mental well-being and QOL in patients with 
MFS. Better management could potentially improve 
an individual’s satisfaction with life by facilitating work 
participation and everyday activities. 
Usual activities
According to the present findings, having MFS increased 
the risk of reporting problems with usual activities (e.g., 
work, study, housework, family or leisure activities). 
Generally, emotional distress and physical inactivity 
have been found to be significantly correlated with work 
participation (22,23). Studies confirm that the employment 
Figure 1 EQ-5D-5L values in the Marfan syndrome patients vs. the ACHD comparison group. Each dimension consists of 5 levels: no 
problems, slight problems, moderate problems, severe problems and extreme problems. Average values were calculated for all dimensions 












Table 4 Crosswalk Index Value vs. Visual Analog Scale (VAS)
Marfan (mean ± SD) ACHD (mean ± SD) P value
Crosswalk 86.97±15.12 90.67±15.51 0.025*
VAS 72.58±15.95 76.23±19.04 0.073
*, significant finding. ACHD, adults with congenital heart defects; SD, standard deviation.
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rate among patients with MFS is considerably below that of 
the general population (24,25). Workplace discrimination 
and stigma are further factors that compound other 
difficulties in the daily lives of patients with MFS (26). 
Peters et al. found that 32% of adults with MFS reported 
feeling socially discriminated against and 20% of patients 
perceived instances of workplace discrimination. For 
this reason, these patients chose to withdraw from social 
situations or keep their illness secret (7,26). Eighty percent 
of patients also reported reducing work hours due to MFS 
or missing on average of 6.5 to 7 months of work because 
of their treatment (20). Social stigmatization is significantly 
correlated with mental illness, pessimistic outlook towards 
MFS and low self-esteem (26). These findings indicate the 
necessity of offering individuals with MFS psychological 
assistance in order to facilitate their coping strategies and 
improve long-term outcomes.
Mobility
MFS was significantly associated with the occurrence of 
mobility impairments which is hardly surprising given the 
findings related to pain in patients with MFS. Symptoms 
commonly associated with MFS, such as chronic pain and 
fatigue, may lead to restricted mobility and lower QOL in 
the physical domain (27). Physical QOL issues have been 
found to be particularly related to age and the presence of 
scoliosis. Additionally, chronic pain was correlated with 
severe mental and physical fatigue which is ranked as one 
of the highest complaints in patients with MFS (20). Until 
now, it is unclear whether fatigue is linked to medication 
use, or inherent symptoms related to MFS itself (4). 
Further research is needed to investigate the exact etiology 
of fatigue in patients with MFS and eventually reveal 
modifiable features of MFS which could be considered in 
their treatment to improve their QOL. 
Anxiety/depression
In accordance with earlier findings, patients with MFS 
experienced considerable impairments in the emotional 
area. Anxiety and depression have been recognized as bio-
behavioral variables, that have the strongest and most direct 
effects on QOL among all disease-related factors (28). 
Peters et al. found that over 40% of their study cohort had 
a significant degree of depressive symptoms (7). Emotional 
distress is known to have far-reaching implications for 
adverse psychological outcomes, such as body image 
dissatisfaction, negative illness perceptions and decreased 
self-esteem (4,29), as well as negative cardiovascular 
consequences, including increased morbidity and premature 
mortality (14,15). As patients sometimes present no 
observable physical signs, they frequently report feeling 
invisible in the health care system and struggle to find 
adequate treatment (7). Based on these findings, clinicians 
need to consider that psychological features that may lie 
beyond cardinal features of MFS may potentially play an 
equally important role in a patient’s quality of life. 
Visual Analog Scale vs. Index values
The two-fold measure of the EQ-5D-5L made it possible 
to investigate variations in QOL as determined by each of 
these two types of measurement. Apparently, the overall 
VAS score indicated a significantly lower QOL than that 
demonstrated by the descriptive index value, for both 
populations. It is conceivable that the descriptive system 
encourages a patient to examine QOL from different 
perspectives as it breaks down QOL into psychological, 
social, physical components. This goes along with Moons’ 
operationalization of QOL as: “the degree of overall life 
satisfaction that is positively or negatively influenced by an 
individual’s perception of certain aspects of life that are important 
to them, including matters both related and unrelated to 
health” (30). Thus, QOL is regarded as a multidimensional 
concept that is influenced by subjective evaluations of both 
positive and negative aspects of life (31). On the contrary, 
VAS picks up a one-dimensional view of perceived health, in 
which patients may be primarily focused on somatic health 
restrictions associated with their MFS.
Conclusions
Remarkably few studies have been undertaken to 
systematically assess psychosocial aspects of MFS. The 
present results provide evidence that individuals with 
verified MFS are likely to experience diminished QOL, 
in both mental and physical domains. Considerable 
restrictions in their QOL become even more evident when 
comparing the study group to patients with other forms of 
CHD. It is therefore important to consider the psychosocial 
consequences of MFS which cost resources for both, 
patients and professionals (e.g., time, money and emotional 
energy). Clinicians can help patients with MFS to reduce 
this cost by making mental health and psychosocial support 
an integral part of cardiac care for MFS.
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